17 studies found for:    "Indolent B cell lymphoma"
Show Display Options
RSS Create an RSS feed from your search for:
"Indolent B cell lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting High Dose Rituximab for Initial Treatment of Indolent B-Cell Lymphomas
Conditions: B-cell Lymphoma;   Indolent B-cell Lymphoma
Intervention: Drug: rituximab
2 Recruiting A Phase I Trial of DI-B4 in Patients With Advanced CD19 Positive Indolent B-cell Malignancies
Conditions: Indolent B-cell Lymphoma;   Chronic Lymphocytic Leukaemia
Intervention: Drug: DI-B4
3 Suspended Treatment of Relapsed or Chemotherapy Refractory Chronic Lymphocytic Leukemia or Indolent B Cell Lymphoma Using Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19
Condition: Leukemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide
4 Active, not recruiting Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
Conditions: Follicular Lymphoma;   Marginal Zone Lymphoma;   Small Lymphocytic Lymphoma
Intervention: Drug: ofatumumab
5 Not yet recruiting Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies
6 Withdrawn Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas
Conditions: Lymphoma, Non-Hodgkin;   Lymphoma, Follicular;   Lymphoma, B-Cell, Marginal Zone;   Lymphoma, Low-Grade;   Lymphoma, Intermediate-Grade
Intervention: Drug: Ofatumumab
7 Completed VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: B-Cell Lymphoma;   Follicular Lymphoma;   Marginal Lymphoma
Intervention: Drug: VELCADE and rituximab
8 Terminated A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
Conditions: Leukemia, Lymphocytic, Chronic, B-Cell;   Lymphoma, B-Cell
Intervention: Drug: AEG35156 antisense IV infusion
9 Recruiting Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Bortezomib;   Drug: Romidepsin
10 Completed
Has Results
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
Conditions: Lymphoma, Non-Hodgkin;   Non-Hodgkin's Lymphoma
Intervention: Biological: tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)
11 Completed Vaccine Therapy Plus Sargramostim Following Chemotherapy in Treating Patients With Stage III or Stage IV Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: keyhole limpet hemocyanin;   Biological: sargramostim;   Biological: tumor cell-based vaccine therapy
12 Unknown  Dendritic Cell Vaccine in Treating Patients With Indolent B-Cell Lymphoma or Multiple Myeloma
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine;   Biological: autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine;   Biological: autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine
13 Completed Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Intervention: Drug: bortezomib + rituximab
14 Unknown  Rituximab, Vaccine Therapy, and GM-CSF in Treating Patients With Non-Hodgkin's Lymphoma
Condition: Lymphoma
Interventions: Biological: autologous immunoglobulin idiotype-KLH conjugate vaccine;   Biological: rituximab;   Biological: sargramostim
15 Active, not recruiting Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Chronic Lymphocytic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: therapeutic autologous lymphocytes;   Drug: cyclophosphamide;   Biological: aldesleukin;   Genetic: polymerase chain reaction;   Genetic: gene rearrangement analysis;   Procedure: lymph node biopsy;   Biological: genetically engineered lymphocyte therapy;   Procedure: bone marrow aspiration;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: enzyme-linked immunosorbent assay
16 Unknown  Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)
Conditions: Immunocytoma/Morbus Waldenström;   B-Cell Non-Hodgkin's Lymphoma;   B-Cell Chronic Lymphocytic Leukemia
Intervention: Drug: Cyclophosphamide, Pentostatin, Rituximab
17 Withdrawn Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma
Condition: Lymphoma
Interventions: Biological: recombinant interferon alfa;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate

Indicates status has not been verified in more than two years